2024 Wisconsin Multiple Myeloma & Lymphoma Summit

Milwaukee, WI US
August 17, 2024

This CME-accredited activity, Wisconsin Multiple Myeloma & Lymphoma Summit, features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of multiple myeloma, lymphoma, and Waldenström Macroglobulinemia.

This activity aims to improve learners' knowledge and competence to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in newly diagnosed and relapsed multiple myeloma and lymphomas with a focus on emerging immunotherapies, including but not limited to CAR-T therapy and T-cell redirecting bispecific antibodies. Expert faculty will aim to place the role of different therapeutic agents in clinical contexts and discuss how to utilize these therapeutic options to effectively contribute to patient care.

Target Audience

  • Cancer care professionals

  • Practicing medical oncologists/hematologists

  • Radiation oncologists
  • Pathologists

  • Medical oncology and hematology fellows

  • Oncology nurses

  • Nurse practitioners

  • Physician assistants

  • Pharmacists

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review strategies for induction and treatment for both transplant-eligible and transplant-ineligible with newly diagnosed multiple myeloma
  • Outline the management strategies for patients with 1-3 prior lines of therapy

  • Review indications and safety of CAR-T, bispecific antibodies MM, and lymphoma

  • Review the indications for the treatment of Waldenstrom Macroglobulinemia and current therapeutic strategies

  • Understand the evolving treatment strategies for the initial management of DLBCL

 

ORGANIZING COMMITTEE: 

Course Director:

Binay Shah, MD, MHA - Binaytara Foundation

 

Conference Co-Chairs:

Binod Dhakal, MD - Medical College of Wisconsin

Timothy Schmidt, MD - University of Wisconsin

 

Hotel information

Coming soon

Course summary
Available credit: 
  • 4.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 4.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 4.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 4.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 4.75 Contact Hours.
Course opens: 
04/19/2024
Course expires: 
12/31/2024
Event starts: 
08/17/2024 - 8:00am PDT
Event ends: 
08/17/2024 - 4:00pm PDT
Cost:
$350.00

August 17th, 2024

All times are listed in Central Time (CT)

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:20 AM  Addressing Global Cancer Health Disparities - Building a 200-Bed Cancer Hospital In Nepal - Justin Marquart


08:20 AM – 09:45 AM  Session 1: Approach to Newly Diagnosed Multiple Myeloma

Session Chair: Timothy Schmidt, MD

08:20 AM – 08:40 AM  Approach to Newly Diagnosed MM - How to Build the Optimal Induction Regimen - Othman S. Akhtar, MD

08:40 AM – 09:00 AM  Maintenance Therapy After Frontline Therapy—Single, Doublet or None?

09:00 AM – 09:45 AM  Debate—Is MRD Ready for Prime Time? - Natalie Callander, MD & 


09:45 AM – 10:15 AM  Break & Exhibits


10:15 AM – 11:40 AM  Session 2: Relapsed and Refractory Myeloma and Emerging Therapies

Session Chair: Binod Dhakal, MD, MS

10:15 AM – 10:35 AM  CAR-T vs SOC in Early Line? - Zhubin Gahvari, MD

10:35 AM – 10:55 AM  Novel Approaches to Treat Late Relapses - Joselle Cook, MBBS

10:55 AM – 11:40 AM  Discussion — How to Treat Patients Progressing after Anti-BCMA CAR-T Therapy - Sandra P. Susanibar-Adaniya, MD


11:40 AM – 12:40 PM  Lunch & Exhibits


12:40 PM – 01:50 PM  Session 3: Management of Non-Hodgkin Lymphoma

Session Chair:

12:40 PM – 01:00 PM  Shifting Landscape in DLBCL

01:00 PM – 01:20 PM  New Updates in MCL

01:20 PM – 01:50 PM  Debate—CAR-T vs. BsAb in DLBCL


01:50 PM – 03:00 PM  Session 4: Miscellaneous

Session Chair:

01:50 PM – 02:10 PM  How I Treat Hodgkin Lymphoma? - Christopher D'Angelo, MD

02:10 PM – 02:30 PM  What is the Latest in AL Amyloidosis? - Morie Gertz, MD, MACP

02:30 PM – 03:00 PM  Debate—BTKi vs. BCL2i in Frontline Therapy for CLL


03:00 PM  Adjourn

Hyatt Regency Milwaukee
333 W Kilbourn Ave
Milwaukee, WI 53203
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Speaker/Topic Presenter(s)

Natalie Callander

has no relevant financial relationships to disclose at this time.

Joselle Cook

has no relevant financial relationships to disclose at this time.

Christopher D'Angelo, MD

has a financial relationship (Grant Or Contract) with Fate Therapeutics;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Grant Or Contract) with Ono Pharma;.
has a financial relationship (Grant Or Contract) with Curis Inc;.
has a financial relationship (Grant Or Contract) with Ono Pharma Inc;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Beigene;.
has a financial relationship (Grant Or Contract) with Seagen;.

Morie Gertz, md macp

has a financial relationship (Professional Services) with Ionis/Akcea, honorariaum from Alnylym, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, personal fees from Aptitude Healthgrants and personal fees from Ashfield Meetings personal fees from Juno, personal fees from Ph;.

Sandra Susanibar-Adaniya, MD, MS

has a financial relationship (Professional Services) with Sanofi;.

Available Credit

  • 4.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 4.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 4.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 4.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 4.75 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.